Sanifit   Report issue

For profit Phase 3
Founded: Palma de Mallorca Spain (2007)
Status: Acquired by Vifor Inc. (2021) → now CSL Behring (2021)

Organization Overview

First Clinical Trial
2016
NCT02790073
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Laboratoris Sanifit | Sanifit Chief Medical Officer | Sanifit Therapeutics | Sanifit Therapeutics S. A.

Active Ingredients

Drugs in Phase 3 Trials (1)

snf472 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Calcinosis (Phase 2)

Calciphylaxis (Phase 3)

Cardiovascular Abnormalities (Phase 2)

Cardiovascular Diseases (Phase 2)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2)

Vascular Calcification (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1